Bank of America
RARE icon

Bank of America’s Ultragenyx Pharmaceutical RARE Stock Holding History

Bank of America’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-30,000
Closed -$1.24M – 8398
2022
Q3 		$1.24M Buy
+30,000
New +$1.54M ﹤0.01% 4707
2021
Q2 		– Sell
-25,000
Closed -$2.85M – 8021
2021
Q1 		$2.85M Buy
+25,000
New +$3.4M ﹤0.01% 3933
2020
Q2 		– Sell
-35,700
Closed -$1.59M – 7073
2020
Q1 		$1.59M Sell
35,700
-5,600
-14% -$291K ﹤0.01% 3658
2019
Q4 		$1.76M Buy
+41,300
New +$1.7M ﹤0.01% 4099

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Bank of America's RARE Position: Q1 2026 in Review

Bank of America reduced its Ultragenyx Pharmaceutical (RARE) stake by 14% in Q1 2026, selling an estimated $3.77M and leaving 1,046,546 shares worth $21.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2305.

Bank of America first reported a position in RARE in Q1 2014 and has held it in 49 quarters since. The position peaked at $51.4M in Q3 2024. 296 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • Bank of America held 1,046,546 shares of Ultragenyx Pharmaceutical worth $21.9M as of Q1 2026.
  • Bank of America sold 167,382 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $3.77M.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #2305 holding.
  • Bank of America first reported a position in Ultragenyx Pharmaceutical in Q1 2014 and has held it in 49 quarters since.
  • Bank of America's Ultragenyx Pharmaceutical position peaked at $51.4M in Q3 2024.
  • 296 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.